Intranasal Foralumab, a novel biologic therapy, has demonstrated remarkable potential in the management of multiple sclerosis. The FDA’s decision to allow patients to self-administer this treatment at home marks a significant advancement in the accessibilit...
Tiziana Life Sciences, Ltd. has announced the publication of a review article in Nature Reviews Neurology, which highlights the potential of its lead drug candidate, intranasal foralumab, for treating various neurodegenerative diseases like Multiple Sclerosis (MS), Alzheimer’s disease, ALS, and Pa...
the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other active clinical sites in the study include Brigham and Women’s Hospital (BWH) and...
“We are pleased to announce the commencement of dosing in the second intermediate-sized patient cohort for our na-SPMS Expanded Access Program,” said Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. “Our dedication to adva...
Tiziana's lead candidate, intranasal foralumab, is currently being studied in other neurodegenerative diseases, including Multiple Sclerosis and Alzheimer's disease. The company aims to provide innovative solutions for ALS patients, addressing an urgent unmet need in the field of ...
25 Mar 2025 Tiziana Life Sciences plans a 6-month open-label extension (OLE) study for Multiple sclerosis 11 Mar 2025 Brigham and Women's Hospital plans II trial for Multiple system atrophy in the US in April 2025 (Intranasal) (NCT06868628) 05 Mar 2025 Tiziana Life Sciences files an IN...
(mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy n...
Howard L. Weiner, MD,is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Center for Neurologic Diseases...
foralumab phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study multiple sclerosis trial potential access to this treatment,” Tanuja Chitnis, MD, professor of neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, said in a ...
s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This Phase 2 compou...